Provider review
Alan Health Review: What Its GLP-1 Plans Actually Cost
Alan Health advertises four different GLP-1 entry prices on one banner, and the cheapest one is the shortest plan. Its headline rate is a two-month prepay; its twelve-month and six-month plans are both quoted higher per month. That is the reverse of how plan pricing normally works, and nothing on the page explains it. On the claims side, Alan is careful where it counts: it reserves the words “FDA-approved” for the four branded drugs it also sells, and states plainly on its compounded product page that compounded medicines are not.
Correction, August 2026
This review previously said: “Alan Health calls its compounded GLP-1 injections FDA-approved in six places. Its own page says they come from compounding pharmacies. Both cannot be true.”
That was wrong. Alan sells four branded, genuinely FDA-approved drugs on the same product grid as its compounded ones, and every branded card carries an "FDA Approved" badge above a description using the phrase. The three sentences this review quoted as Alan's claim about its compounded product are those branded cards' own descriptions — two belong to Wegovy and one to Mounjaro. We cannot tell you whether the copy moved after 14 August or whether the original read joined a badge to the wrong card, and either answer would be a guess. A grid that alternates approved and compounded rows is exactly where a reading like this goes wrong, and the fix is to attribute every quoted sentence to the card it sits on before publishing it.
It now says: Re-read 2026-08-25. "FDA-approved" appears ten times across the home and weight-loss pages, and every occurrence is on a Wegovy, Zepbound, Ozempic or Mounjaro card. The compounded rows read "Prescription compounded Semaglutide injections with personalized dosing" and claim no approval. The compounded product page states: "Compounded medications are not FDA-approved; results vary." On the evidence available today, Alan labels the distinction correctly, and this review no longer says otherwise. Its open FDA warning letter, which concerns the name on the pictured labels rather than any advertising copy, is unaffected and stands as recorded below.
Prices four different GLP-1 entry rates on one banner, with the shortest plan cheapest per month and nothing on the page explaining why. On the regulatory question it is careful: the approval claims belong to the branded drugs it sells, and its compounded page says compounded medicines are not FDA-approved.
Worth trusting if
- You want the compounded-versus-approved line drawn for you — Alan sells both and says which is which on every card
- You will prepay two months, because that is the plan the headline rate belongs to
- You want a low entry price and will confirm the renewal rate before paying, since none is published
Be skeptical if
- You are comparing per-month rates across plan lengths — the twelve-month and six-month plans are quoted higher per month than the two-month one
- You want a named pharmacy or a published test result, because neither exists here
- You will not create a password-protected account, because the signup demands one at the second screen
Compounded only
Phase 3 trials
Not named
February 2026
Disclosure: Some links on this site are affiliate or referral links. If you start a treatment or buy a product through them, we may earn a commission at no additional cost to you. Read our full disclosure.
Opens www.alanmeds.com. A link is not a recommendation to take anything.
Provenance
What Alan Health actually dispenses
Regulatory category is the axis consumers are most reliably misled about, so it comes first. Every product below is sorted by what it legally is, not by what it costs.
Prepared by a state-licensed pharmacy against a prescription for a named patient. Compounded preparations are not FDA-approved and are not reviewed by FDA for safety, effectiveness or quality.
- Compounded GLP-1 injection — Read 2026-08-10 as one figure with an unresolved asterisk. Re-read 2026-08-25: the asterisk is resolved, and there are four GLP-1 entry rates on one banner rather than one. $158/mo is the headline, and its footnote reads "Paid upfront with a 2-month plan. Actual price will depend on the product and plan purchased." Beside it the same banner offers $195/mo on twelve-month plans and $215/mo on six-month plans — so the longer commitments are quoted higher per month than the two-month one, which is the reverse of how this market normally prices term. Nothing on the page reconciles the three, and no renewal rate is published for any of them. Microdosing GLP-1 starts at $145/mo paid upfront on six months, and B12/MIC at $105/mo on six.
Evidence
Has the molecule been tested for what it is sold for?
One row per product, graded on how far the published human evidence goes for the MOLECULE inside it, for the use it is sold for — not for the molecule in general, and never a claim about this seller. Nobody trials a compounded preparation; what a trial can tell you is whether the molecule has been tested for the thing it is being advertised to do. A molecule with phase 3 evidence for one outcome has none for another, and that distinction is where peptide marketing lives.
1
Molecules with human evidence
For the use they are sold for, out of 1 products reviewed here. The evidence belongs to the molecule, not to Alan Health.
1
Registry records cited
Each read live from ClinicalTrials.gov, never from memory. None of them tested this company's product.
The comparison
What they claim, against what the trials show
Each claim below is quoted verbatim from Alan Health’s own page, with the page it came from. Grading a paraphrase would prove nothing. Every row is the verdict at a glance — tap it to open the quote, the trial registry entries, and the full note behind that verdict.
Compounded GLP-1 injectionSemaglutide · Compounded (503A)Claim matches the trials
“In Stock — Personalized Compounded Semaglutide — Prescription compounded Semaglutide injections with personalized dosing. […] Compounded Semaglutide may include B6, B12, Glycine, and NAD+. […] Medication may be prescribed by a licensed provider when clinically appropriate and dispensed by a compounding pharmacy. Compounded medications are not FDA-approved; results vary. […] U.S. compounded medications from 503a and 503b pharmacies”
Read on the Alan Health site, August 2026
Phase 3 trials
What the trials show for Semaglutide
- NCT03548935 STEP 1 — Phase 3, completed, n=1,961. Semaglutide 2.4 mg over 68 weeks — the trial that supports the FDA-approved product, not a compounded preparation.
Re-read 2026-08-25, and this row is now graded the opposite way round from how it was published on 14 August — see the correction at the top of the page. Alan makes no efficacy claim for its compounded semaglutide at all. The card says "Prescription compounded Semaglutide injections with personalized dosing", which is a description of what it is, not a promise about what it does, and there is no percentage, no timeline and no trial reference. The product page then prints the disclosure that matters: "Compounded medications are not FDA-approved; results vary." The words "FDA-approved" do appear across these pages, ten times between the home and weight-loss pages, and every one of them sits on a Wegovy, Zepbound, Ozempic or Mounjaro card carrying an "FDA Approved" badge — four drugs that are FDA-approved. Selling approved brands beside compounded copies on one grid puts a real burden on the labeling, and here the labeling carries it. Two things still deserve a reader's attention: the compounded preparation "may include B6, B12, Glycine, and NAD+", so it is not the molecule the phase 3 trials tested even before you get to the compounding question, and "personalized dosing" is not a regimen any registered trial has run.1
Dispensing chain
Who actually fills your prescription
Read the full account
No pharmacy is named. Alan says it supplies “U.S. compounded medications from 503a and 503b pharmacies” and refers to “vetted pharmacy partners” and “trusted pharmacy partners”, but identifies none, so neither regulatory category can be checked against a licensee. Naming both 503a and 503b without saying which applies to which product is itself unclear: the two are different regulatory regimes with different oversight.
Read on the Alan Health site, August 2026.
Quality
Third-party testing, and what is published
Describes a testing regime
Nothing published on the pages searched
Certificate of analysis readable
No lot report a buyer can open
Read the full testing account
No certificate of analysis, potency result, purity result or third-party test is published or offered, and no pharmacy is named that could be asked for one. Re-checked 2026-08-25: the compounded product page does carry a quality section describing a testing program — "USP-compliant sterility and endotoxin screens", "verified potency", "Testing follows current USP chapters, FDA guidance, and cGMP best practices", footnoted to USP <797> and USP <85>. That names the standards being worked to, which is more than most of this market does. It is still a description of a process rather than a result for any batch, and there is no lot number, no laboratory and no document to read.
Read on the Alan Health site, August 2026.
Licensing
Licensed to dispense, and where
Coverage
No state list or set of exclusions is published on the public pages. Delivery is stated as three days or less from its pharmacy partners, without naming the jurisdictions served.
Read the full licensing claim
U.S. compounded medications from 503a and 503b pharmacies
Read on the Alan Health site, August 2026.
Regulatory
The FDA warning letter
Issued February 2026
Alan Health Technologies Inc. dba Alan — MARCS-CMS 721814. Concerns marketing and labeling.
Read the full allegation
FDA reviewed the website at https://www.alanmeds.com in December 2025 and cited its representations as false or misleading under FD&C Act sections 502(a) and 502(bb). The letter's single finding: "The compounded semaglutide and tirzepatide products displayed on your website identify 'Alan' on the pictured label, suggesting Alan is the compounder of those drugs when in fact it is not." It quotes no advertising copy, makes no allegation about sterility, potency, contamination or any other product-quality matter, and states its citations are "not intended to be an all-inclusive statement of violations."
We did this ourselves
What happens when you sign up with Alan Health
We went through Alan Health’s signup ourselves in August 2026 to find out what you actually meet before you pay — the steps, when a price appears, and what it asks for. We used placeholder answers, and we stopped before paying, so nothing here is a prescription or a medical outcome. It is what the screens showed.
- Pick a product from the weight-loss grid and press "Get started". Every price you will be quoted is already on the banner above it.
- The visit opens on health.alanmeds.com and asks for an email address before anything else.
- The next screen is "Create an account" — first name, last name, and a password of at least eight characters with an uppercase letter, a number and a symbol, plus a terms and telehealth consent box.
- This walk stopped there. We do not create password-protected accounts, so nothing past that screen was seen.
- Four GLP-1 entry rates sit on one banner before any question: $158/mo, $195/mo on twelve-month plans, $215/mo on six-month plans, and $105/mo for B12/MIC on six months.
- The cheapest rung is the shortest commitment. $158/mo is footnoted "Paid upfront with a 2-month plan", while the twelve- and six-month plans are quoted higher per month — the reverse of how plan length usually works.
- Every advertised figure is a prepay rate. No renewal price is published for any plan, so what you pay in month three is not on the site.
- The product grid mixes four approved brands with the compounded rows, and the approved ones carry an "FDA Approved" badge. The compounded rows carry none, and the compounded product page says compounded medicines are not FDA-approved.
- The compounded semaglutide "may include B6, B12, Glycine, and NAD+", which is stated in a footnote under the ordering steps rather than on the product itself.
- The visit demands an account with a password at its second screen, before a single medical question and before any price is confirmed.
- A "Virtual consultation" is listed as step two of the advertised process: "Chat with a US-certified doctor to get your prescription."
Alan Health support
- Phone
- 855-837-6337
- help@alanmeds.com
Assessment
What holds up, and what does not
- Its compounded product page states "Compounded medications are not FDA-approved; results vary" — the disclosure two companies in this market hold open FDA letters for omitting.
- It reserves the words "FDA-approved" for the four branded drugs it also sells, each of which is.
- The asterisk on the headline price is resolved in the same banner: "Paid upfront with a 2-month plan."
Show 4 more
- It names its regulatory categories — 503a and 503b — rather than saying only “licensed pharmacy”, which is more specific than much of this category manages.
- The operating company is named: Alan Health Technologies, Inc.
- The entry price is among the lower ones published for a compounded GLP-1.
- Delivery timing is stated concretely as three days or less.
- One banner carries four GLP-1 entry rates, and the twelve-month and six-month plans are both quoted higher per month than the two-month one. Nothing on the page reconciles them.
- Every advertised figure is an upfront prepay rate, and no renewal price is published for any plan.
- Approved brands and compounded copies sit on one grid, so the badge is doing all the work of telling them apart.
Show 6 more
- The compounded preparation "may include B6, B12, Glycine, and NAD+", which is not what the phase 3 trials tested.
- No pharmacy is named, so neither the 503a nor the 503b claim is checkable.
- It cites 503a and 503b together without saying which applies to what — they are different regimes with different oversight.
- No certificate of analysis or test result is published.
- An open FDA warning letter (721814, February 2026) found the pictured product labels implied Alan compounds the drugs itself.
- The signup demands a password-protected account at the second screen, before any medical question or any price is confirmed.
Verdict
The bottom line
Do not use this site to answer whether your medication is FDA-approved, because it gives both answers. If the product is compounded — and Alan says it is — then it has not been through FDA review, and the phase 3 evidence a reader has in mind belongs to Wegovy and Ozempic rather than to what arrives in the vial.
Opens www.alanmeds.com. A link is not a recommendation to take anything.
What a month costs, and which month
Alan's banner carries four GLP-1 entry prices at once, before you answer anything:
- $158/mo — the headline, footnoted "Paid upfront with a 2-month plan"
- $195/mo — "12-Month Plans Available"
- $215/mo — "6-Month Plans Available"
- $105/mo — B12/MIC, six-month plans
Read that ladder twice. In this market a longer commitment normally buys a lower monthly rate; here the twelve-month and six-month plans are both quoted above the two-month one. Nothing on the page reconciles them, and the footnote only says "Actual price will depend on the product and plan purchased" — which is true and is not an answer.
Every one of those figures is a prepay rate. No renewal price is published for any plan, so the site does not tell you what month three costs.
Re-checked on 25 August 2026, the asterisk itself is resolved, and an earlier version of this review said it never was. That correction is recorded above.
Full analysis — 5 more sectionsApproved and compounded, on one grid · What is actually in the vial · What the FDA letter does and does not cover · What is not published · Where the visit stops
Approved and compounded, on one grid
Alan sells both. On the weight-loss page the rows run:
"In Stock — Personalized Compounded Semaglutide — Prescription compounded Semaglutide injections with personalized dosing."
"Limited Supply · FDA Approved — Wegovy® (semaglutide) — Manage weight with a once-weekly, FDA-approved injection."
That is the arrangement most likely to mislead a hurrying reader, and it is where this review previously went wrong itself — see the correction at the top of the page. On today's site the labeling holds up: the phrase "FDA-approved" appears ten times across the home and weight-loss pages and every occurrence belongs to Wegovy, Zepbound, Ozempic or Mounjaro, each with an "FDA Approved" badge. Those four drugs are approved. The compounded rows claim nothing of the kind, and the compounded product page prints the sentence that settles it:
"Compounded medications are not FDA-approved; results vary."
That is the disclosure two companies reviewed on this site hold open FDA letters for leaving out.
What is actually in the vial
One line in a footnote under the ordering steps is worth more attention than the badge argument:
"Compounded Semaglutide may include B6, B12, Glycine, and NAD+."
So the product is a combination preparation, not the molecule STEP 1 tested. 1 Add "personalized dosing" — a regimen no registered trial has run — and the distance between what the trials measured and what ships is larger than the compounding question alone suggests. Alan does not claim otherwise; it makes no efficacy claim for this product at all. A reader carrying the phase 3 numbers in their head should know they were not measured on this.
What the FDA letter does and does not cover
Alan Health Technologies has an open warning letter, 721814, from February 2026. Its single finding is narrow: the compounded products pictured on alanmeds.com "identify 'Alan' on the pictured label, suggesting Alan is the compounder of those drugs when in fact it is not", citing 21 CFR 201.1(h)(2). No advertising copy is quoted in the letter at all, and nothing in it concerns sterility, potency or contamination. It is disclosed here, dated, and left to speak for itself.
What is not published
No pharmacy is named — so neither the 503a nor the 503b claim can be checked, and there is nobody to ask for a certificate of analysis, which is not published either. There is a quality section describing sterility and endotoxin screening to USP <797> and USP <85>, which names the standards being worked to; it is a description of a process, not a result you can read.
Where the visit stops
The signup asks for an email, then demands a password-protected account on its second screen — before any medical question and before any price is confirmed. This walk stopped there.
Questions
Frequently asked questions
Is Alan Health's compounded GLP-1 FDA-approved?
No, and Alan says so. Its compounded product page reads "Compounded medications are not FDA-approved; results vary." Compounded preparations are made to a prescription by a state-licensed pharmacy and are not reviewed by FDA for safety, efficacy or quality. Alan also sells four drugs that are approved — Wegovy, Zepbound, Ozempic and Mounjaro — on the same grid, each with an "FDA Approved" badge, and every use of the phrase on those pages belongs to one of them. An earlier version of this review said otherwise; the correction is at the top of the page.
Does the trial evidence apply to what Alan sells?
Not directly. The phase 3 trials tested the branded, approved products. A compounded preparation is a different article — potentially the same molecule, but not the product that was studied and not reviewed for how it was made. Here the gap is wider than usual for a specific reason Alan states in a footnote: its "Compounded Semaglutide may include B6, B12, Glycine, and NAD+", so it is a combination preparation, given at a "personalized" dose no registered trial has run. Alan makes no efficacy claim for it, which is the right answer, but a reader arriving with the trial numbers in mind should know those numbers were measured on something else.
Does Alan Health have an FDA warning letter?
Yes — 721814, issued 20 February 2026 and open. It quotes no advertising copy; its single finding is that the pictured product labels carried Alan's name, implying Alan manufactures the drugs. It makes no allegation about sterility, potency or contamination, and FDA has published no close-out letter. A letter is disclosed here and dated; it is not treated as a verdict on the medication.
Compare
Others selling what Alan Health sells
Companies we have also reviewed that dispense at least one of the same compounds, ordered by how much of what they say about their products matches the trials behind them. Nothing here is a recommendation, and none of these links earns us anything.
Method
How we checked this
Non-product facts last checked August 2026. Read the editorial policy for the rules this page is held to.
Read our methodology
Claims read first-party
Every quoted claim was read off Alan Health's own pages, first-hand, on the date stamped against it — never from a summary, an aggregator, or an earlier version of this review.
Trials read from the registry
Phase, status and enrollment come from ClinicalTrials.gov; identifiers and journals from PubMed's own records. Nothing here is cited from memory.
Absence claims bounded
Where we report that no trial exists, the page says what was searched, where, and when — never an unbounded claim that nobody has tested something.
Letters matched on full name
FDA letters are matched on the complete company name. A substring match would attach one firm's regulatory history to another with a similar name.
Sources
References
Show all 2 sources
- Wilding JPH, Batterham RL, Calanna S, et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine 384(11):989-1002. https://pubmed.ncbi.nlm.nih.gov/33567185/
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine 387(3):205-216. https://pubmed.ncbi.nlm.nih.gov/35658024/
Medical disclaimer: This content is for general educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.